Bridgewater Associates LP lessened its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 52.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,398 shares of the biopharmaceutical company’s stock after selling 6,972 shares during the period. Bridgewater Associates LP’s holdings in Alexion Pharmaceuticals were worth $778,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of ALXN. BlackRock Inc. raised its position in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after purchasing an additional 17,960,356 shares in the last quarter. Bank of Montreal Can raised its position in Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock worth $173,174,000 after purchasing an additional 1,228,025 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in Alexion Pharmaceuticals by 42.2% in the second quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock worth $391,773,000 after purchasing an additional 955,578 shares in the last quarter. Bessemer Group Inc. raised its position in Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock worth $87,772,000 after purchasing an additional 721,367 shares in the last quarter. Finally, State Street Corp raised its position in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after purchasing an additional 718,756 shares in the last quarter. 94.26% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/17/bridgewater-associates-lp-sells-6972-shares-of-alexion-pharmaceuticals-inc-alxn.html.

In related news, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock worth $2,416,869 over the last ninety days. 4.35% of the stock is currently owned by insiders.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 146.69 on Friday. The stock’s 50 day moving average is $138.83 and its 200 day moving average is $124.75. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a market capitalization of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.13 EPS. On average, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.62 EPS for the current fiscal year.

Several research analysts recently issued reports on ALXN shares. Barclays PLC reissued an “overweight” rating and issued a $155.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. UBS AG reissued a “buy” rating and issued a $142.00 price target (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. Deutsche Bank AG dropped their price target on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Thursday, May 25th. Morgan Stanley reissued an “overweight” rating and issued a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, J P Morgan Chase & Co raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $163.00 to $175.00 in a research note on Tuesday, September 5th. Five investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $157.13.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.